Related Experiment Video
Updated: May 9, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024
Marc Xipell1, Maria Iraola1, Safak Mirioglu2,3
1Department of Nephrology and Renal Transplantation, Clinic Barcelona, Spain; Reference Center for Complex Glomerular Diseases of the Spanish Health System (CSUR), Department of Medicine, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
None:
Lupus nephritis (LN) is a major driver of morbidity and kidney failure in systemic lupus erythematosus, and its management has grown substantially more complex with the emergence of targeted therapies. Between 2024 and 2025, the American College of Rheumatology, the European Alliance of Associations for Rheumatology, and Kidney Disease: Improving Global Outcomes each released updated recommendations grounded in a largely shared evidence base but differing in scope, clinical profiling, and operational emphasis. This review compares the three frameworks, highlighting key areas of convergence and divergence relevant to contemporary clinical practice. The main themes include the shift toward early combination regimens targeting complementary immune pathways, driven by the emergence of targeted therapies such as belimumab, voclosporin, and obinutuzumab; the incorporation of clinical profiling to guide therapy selection and monitoring; strategies aimed at rapid glucocorticoid minimization; and the growing recognition of renoprotective therapy as a central pillar of LN care within a chronic kidney disease management strategy.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Nephrotic Syndrome II : Assessment and Medical Management
